Table 1.
Baseline Characteristics
| Total Population | Completing the Study (n = 85) |
|---|---|
| Gender (%M) | 36 (42.3) |
| BMI, mean (range) | 25 (12–44) |
| Age – years, mean (range) | 70.1 (51–94) |
| GOLD (%) | |
| A | 5 (5%) |
| B | 20 (21%) |
| C | 9 (9%) |
| D | 62 (65%) |
| MRC (%) | |
| 1 | 1 (1.2%) |
| 2 | 19 (22.4%) |
| 3 | 33 (38.8%) |
| 4 | 25 (29.4%) |
| 5 | 11 (7.7%) |
| Smoking history | |
| Former smokers no. (%) | 74 (77.1) |
| Current smokers no. (%) | 22 (22.9) |
| Pack years, mean (±) | 45.55 (8–90) |
| Daily dose of ICS, mean (µg) | 740 |
| Lung function | |
| FEV1 | 0.97 (0.25–2.30) |
| FEV1% pred. | 40.55 (12–93) |
| No. of patients with exacerbations prior to inclusion (%) | 45 (52.9) |
| Blood eosinophil conc. | 0.22 (0–1.22) |
| Exa. prior to inclusion | 0.24 (0–1.22) |
| No exa. prior to inclusion | 0.19 (0–0.56) |
| Charlson comorbidity Index | |
| 0 (%) | 15 (15.6) |
| 1 (%) | 28 (29.2) |
| ≥2 (%) | 53 (55.2) |
Abbreviations: %M, percent males; BMI, body mass index; no., numbers; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1st second; pred., predicted; conc., concentration; exa, exacerbations.